Craft

Hua Medicine

Stock Price

$1.8

2024-10-29

Market Capitalization

$1.7 B

2024-10-29

Revenue

¥492.9 M

FY, 2025

Hua Medicine Summary

Company Summary

Overview
Hua Medicine (华领医药) is a drug development company. It focuses on therapies for the treatment of diabetes and CNS disorders. The company develops an oral drug for the treatment of type 2 diabetes.
Type
Public
Status
Active
Founded
2011
HQ
Shanghai, CN | view all locations
Website
https://www.huamedicine.com/En
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Li Chen

    Li Chen, Founder, CEO, Executive Director

  • Robert Taylor Nelsen

    Robert Taylor Nelsen, Chairman

    • George Lin

      George Lin, EVP & Chief Financial Officer, Executive Director

    • George Chien Cheng Lin

      George Chien Cheng Lin, Executive Director

      Operating MetricsView all

      Clinics

      100

      Sep, 2023

      Partners

      21

      Sep, 2023

      LocationsView all

      5 locations detected

      • Shanghai, Shanghai Shi HQ

        China

        No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong

      • Shanghai Shi

        China

        Xue Lin Lu, Xuhui Qu

      • Beijing, Beijing

        China

        Room 7C12, Building 2, Courtyard No.1, Xizhimenwai Street, Xicheng District

      • Wuhan, Hubei Sheng

        China

        Rm2504B, 2505B,25th floor, Yuexiu Fortune Center, No.1 Zhongshan Avenue, Qiaokou District

      • Hong Kong, Hong Kong Island

        Hong Kong

        Methodist House, 36 Hennessy Rd, Wan Chai

      Hua Medicine Financials

      Summary Financials

      Revenue (FY, 2025)
      ¥492.9M
      Gross profit (FY, 2025)
      ¥1.6B
      Net income (FY, 2025)
      ¥1.1B
      Cash (FY, 2025)
      ¥1.1B
      EBIT (FY, 2025)
      ¥1.1B
      Enterprise value
      $896.9M

      Footer menu